Suchergebnisse - "HR+/HER2-advanced breast cancer"

PubPharm (38)

1

Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer

enthalten in: Expert review of pharmacoeconomics & outcomes research | 2024

von Hong, J. | Chen, T. | Ouyang, L. | +6

2

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer : The randomized Tempo Breast study

enthalten in: Breast (Edinburgh, Scotland) | 2024

von Freyer, G. | Martinez-Jañez, N. | Kukielka-Budny, B. | +17

3

First-line CDK4/6 inhibitor-based combinations for HR+/HER2- advanced breast cancer : A Bayesian network meta-analysis

enthalten in: Journal of evidence-based medicine | 2024

von Guo, X. | Zhou, Y. | Zhang, K. | +6

4

A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer

enthalten in: Breast cancer research : BCR | 2024

von Rodón, J. | Demanse, D. | Rugo, H. | +9

5

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study

in: Breast | 2024

von Gilles Freyer | Noelia Martinez-Jañez | Bożena Kukielka-Budny | +17

6

Current treatment landscape of HR+/HER2- advanced breast cancer in the Nordics : a modified Delphi study

enthalten in: Acta oncologica (Stockholm, Sweden) | 2023

von Geisler, J. | Karihtala, P. | Tuxen, M. | +26

7

Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer : analysis based on final OS results of MONALEESA-2 and PALOMA-2

enthalten in: Journal of medical economics | 2023

von Cameron, D. | Kumar Sharma, V. | Biswas, C. | +3

8

PERFORM : a non-interventional study assessing the patients' treatment starting with 1L palbociclib in HR+/HER2- ABC

enthalten in: Future oncology (London, England) | 2022

von Lux, M. | Runkel, E. | Glastetter, E. | +6

9

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study : Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

enthalten in: ClinicalTrials.gov | 2022

10

Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer. : A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease - MONALEESA-2

enthalten in: WHO International Clinical Trials Registry Platform | 2022